Experimental Lilly pill leads to 14.7% weight loss in mid-stage trial - Reuters.com

1diawanita.blogspot.com

June 23 (Reuters) - Results from a mid-stage trial found that the highest dose of Eli Lilly's (LLY.N) experimental pill orforglipron helped people who were obese or overweight lose 14.7% of their body weight after 36 weeks, the company said on Friday.

The pill belongs to a new class of drugs known as incretins that have reignited researcher and investor interest in the weight-loss treatment market, which is estimated to reach $100 billion by the end of the decade.

Results from the Phase 2 study of the once-daily drug were presented in San Diego at the annual meeting of the American Diabetes Association and published in the New England Journal of Medicine.

At the multi-dose trial's 26-week main endpoint, Lilly said orforglipron showed statistically significant dose-dependent body weight reductions ranging from 8.6% (12mg) to 12.6% (45mg), compared with 2% for the placebo group.

For patients on orforglipron, the company said body weight continued to decrease at 36 weeks, with reductions ranging from 9.4% to 14.7%.

Lilly said the safety profile of orforglipron was similar to other incretin-based therapies. Gastrointestinal side effects were the most commonly reported adverse events, were generally mild-to-moderate and usually occurred during the initial dose escalation period.

Orforglipron, like Lilly's injected drug Mounjaro, belongs to a class of drugs that mimic the gut hormone glucagon-like peptide-1, which act to suppress appetite and were initially developed to treat type 2 diabetes.

Lilly reported last year that a trial of Mounjaro in people who were obese or overweight but did not have diabetes found it led to weight loss of 22.5%, or about 52 pounds (24kg).

“We recognize that obesity is a global epidemic and there is a need for a variety of effective medications and administration routes,” weight-loss specialist Dr. Sean Wharton said in a statement. “These exciting results indicate that orforglipron may be an effective, once-daily oral that can be taken without food or water restrictions.”

Lilly is slated to announce later on Friday results from a different Phase 2 trial of orforglipron designed to evaluate the drug as a treatment for adults with type 2 diabetes, as well as full results from a trial of Mounjaro in people with type 2 diabetes who were also obese or overweight.

The company is conducting Phase 3 trials of orforglipron for chronic weight management and for type 2 diabetes.

Reporting by Deena Beasley in Los Angeles Editing by Matthew Lewis

Our Standards: The Thomson Reuters Trust Principles.

Adblock test (Why?)

"stage" - Google News
June 24, 2023 at 04:34AM
https://ift.tt/AieS5P0

Experimental Lilly pill leads to 14.7% weight loss in mid-stage trial - Reuters.com
"stage" - Google News
https://ift.tt/1RzMvef
https://ift.tt/tcMfVia

Bagikan Berita Ini